Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction

•The prevalence of heart failure with preserved ejection fraction among patients who present with symptoms of heart failure is approximately 50%.•Pharmacologic therapy has not conclusively shown benefits in morbidity and mortality in clinical trials.•Although it represents an active area of research, no device-based therapy has received regulatory approval for the treatment of heart failure with preserved ejection fraction.•Approaches such as atrial shunts, left ventricular expanders, mechanical circulatory support devices, and neurostimulators are at various stages of development.